5 Stocks to Invest In Today According to Rob Cope’s Columbus Point

3. Thermo Fisher Scientific Inc. (NYSE: TMO)

Cope’s Stake Value: $19,006,000
Percentage of Rob Cope’s 13F Portfolio: 8.46%
Number of Hedge Fund Holders: 87

Thermo Fisher Scientific Inc. (NYSE: TMO) offers laboratory products, analytical instruments, specialty diagnostics, and life sciences solutions globally. The company was incorporated in 1956 and stands third on the list of 10 stocks to invest in today according to Rob Cope’s Columbus Point. On the other hand, Rob Cope’s bet on Thermo Fisher Scientific Inc. (NYSE: TMO) is also paying off. The company shares are up 32.22% over the last 12 months.

On August 4, Credit Suisse analyst Katie Tryhane initiated a coverage on Thermo Fisher Scientific Inc. (NYSE: TMO) with an “Outperform” rating and $580 price target. On July 28, Thermo Fisher Scientific Inc. (NYSE: TMO) announced earnings for the second quarter of 2021. It posted earnings per share of $5.60, surpassing the estimates by $5.48. Revenue over the period was $9.27 billion, up 34% YoY, beating analyst estimates of $8.73 billion.

Rob Cope’s Columbus Point currently owns 37,675 shares of Thermo Fisher Scientific Inc. (NYSE: TMO) worth over $19 million. Thermo Fisher Scientific Inc. (NYSE: TMO) occupies 5.99% of Columbus Point’s overall equity. In addition, hedge funds are loading up on Thermo Fisher Scientific Inc. (NYSE: TMO), as Insider Monkey’s data shows that 87 hedge funds held stakes in the company in the second quarter of 2021, compared to 79 funds in the first quarter of 2021.

DEVON Equity Management, in its second quarter 2021 investor letter, mentioned Thermo Fisher Scientific Inc. (NYSE: TMO). Here is what the fund said:

“The broad response to the COVID pandemic from the healthcare, pharmaceutical, and life science industries has been nothing short of incredible.

Whilst Vaccine makers understandably garner the highest profile, Thermo Fisher (6.2% of NAV) should be considered one of the outstanding performers, reflected in their ‘COVID related revenue’ hitting US$9.4bn in the 12 months since March 2020 (we appreciate measuring ‘contribution’ to the pandemic by ‘dollars’ generated is a little crude – but ultimately it does tell us something) .…” (Click here to see the full text)